Global Systemic Sclerosis Market Overview
Systemic sclerosis, also known as systemic fibrosis, is an autoimmune rheumatic illness marked by excessive collagen formation and buildup in the skin and internal organs, as well as injury to tiny arteries. Based on the level of skin involvement, there are two broad subtypes of systemic sclerosis: limited and diffuse. With or without facial involvement, the limited form affects areas below, but not above, the elbows and knees. The skin above the elbows and knees is also affected by the diffuse type, which can spread to the torso. The fibrotic process can affect visceral organs such as the kidneys, heart, lungs, and gastrointestinal tract. The Global Systemic Sclerosis Market accounted for US$ 2.2billion in 2020 and is estimated to be US$ 3.6 billion by 2030 and is anticipated to register a CAGR of 5.30%.
Global Systemic Sclerosis Market Dynamics
New pipeline product
Researchers and sponsors are concentrating their efforts on rapidly generating new prospective candidates. The kind and method of action of these pipeline products varies. For example, Kadmon Holdings, Inc. acquired Orphan Medication Designation from the US Food and Drug Administration in September 2020 for its innovative drug candidate, belumosudil (KD025), which is designed to treat systemic sclerosis. Belumosudil (KD025) is a Rho-associated coiled-coil kinase 2 inhibitor with a dual mode of action that targets both immunological and fibrotic components. It is currently being tested in a phase 2 clinical trial.
Absence of validated outcome metrics
The absence of validated outcome metrics and present unique hurdles in drug development, on the other hand, are impeding the market for systemic scleroderma treatment from expanding. The failure of a recent clinical trial adds to the difficulty of developing treatments for this disease. For example, despite promising phase 2 clinical trial findings, Corbus Pharmaceuticals Holdings Inc.'s pipeline candidate Lenabasum failed to show benefits across the primary and secondary endpoints in September 2020.
Global Systemic Sclerosis Market Segmentation
Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.
The Global Systemic Sclerosis Market is segmented based on Drug type, and region.
On the basis of Drug Type, the Global Systemic Sclerosis Market is segmented into Immunosuppressors, PDE-5 Inhibitors, Endothelin Receptor Antagonist, Prostacyclin Analogues
Regional Insights:
Source: Prophecy Market Insights
On region the Global Systemic Sclerosis Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the systemic scleroderma treatment market, accounting for 42.9 percent of total revenue. Biologics are rapidly being used in developed regions, resulting in a larger regional market. The major revenue driver is access to recently developed immunosuppressants combined with a good reimbursement scenario. In the United States, there are around 276 cases of systemic sclerosis per million people and approximately 20 cases of systemic scleroderma per million individuals. Furthermore, the total direct healthcare cost per patient was estimated to be between USD 17,365 and USD 18,396. Generic and over-the-counter medications constitute the major therapy for scleroderma and related symptoms in poorer countries. In Japan, the market for systemic scleroderma treatment is seeing price reductions and new orphan medicines are being introduced more quickly. In Latin America and the Middle East and Africa, growth will be fueled by the predicted rise in access to biosimilar and generic immunosuppressants.
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2030 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Drug Type- Immunosuppressors, PDE-5 Inhibitors, Endothelin Receptor Antagonist, Prostacyclin Analogues |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Systemic Sclerosis Market report based on Drug Type, and region.
Global Systemic Sclerosis Market, By Region:
-
-
- North America
-
- U.S.
- Canada
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- North America
-
Global Systemic Sclerosis Market Key Players
The key players operating in the systemic sclerosis market are F. Hoffmann La Roche Ltd.; Johnson & Johnson Services, Inc.; United Therapeutics; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Pfizer, Inc.; Eli Lilly and Company; Bayer AG; Mylan N.V.; Teva Pharmaceutical Industries Ltd. The underlying factor is a strong preference for immunosuppressants in the treatment of PAH and ILD caused by scleroderma. Due to the increased penetration of this class of medications and their superior efficacy over existing options such as cyclophosphamide, methotrexate, and mycophenolate mofetil, these therapies will reign until the arrival of curatives in clinical trials.
Global Systemic Sclerosis Market Company Profile
- F. Hoffmann La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Johnson & Johnson Services, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- United Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Boehringer Ingelheim International GmbH
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
Global Systemic Sclerosis Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for Systemic Sclerosis Strategies
- Key Questions this Study will Answer
- Market Snippet, By Drug Type
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global Systemic Sclerosis Market, By Drug Type, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Immunosuppressors
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- PDE-5 Inhibitors
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Endothelin Receptor Antagonist
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Prostacyclin Analogues
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Systemic Sclerosis Market, By Region, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Drug Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- F. Hoffmann La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Johnson & Johnson Services, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- United Therapeutics
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Boehringer Ingelheim International GmbH
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
Global Systemic Sclerosis Market is segmented based on drug type and region.
Many product in pipeline is major factor driving the market.
During the forecast period, North America is expected to dominate the market.
The key players operating in the systemic sclerosis market are F. Hoffmann La Roche Ltd.; Johnson & Johnson Services, Inc.; United Therapeutics; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Pfizer, Inc.; Eli Lilly and Company; Bayer AG; Mylan N.V.; Teva Pharmaceutical Industries Ltd.